Sun Pharma and BMS lead 2025 ANDA litigation

According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Pharma

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

10 August 2026 Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.

Pharma

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

6 August 2026 A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

More features

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

Kirkland clears conflicts hurdle in trade secrets spat

Former senior attorney-advisor to ITC commissioners joins Mintz

The UPC plugs another gap in its procedural rulebook

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

Brown Rudnick lands largest lateral IP team hire in firm history

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

K&L Gates expands European practice with Munich team hire

Sun Pharma and BMS lead 2025 ANDA litigation

More on this story

Editor's picks

Editor's picks

More features